Solventum (SOLV) 2024 Wells Fargo Healthcare Conference summary

Strategic vision and transformation

• Leadership team brings prior spin-off and transformation experience, aiming to replicate past value creation successes in a new med tech environment.

• Focus on building a strong mission-driven culture, accelerating talent upgrades, and ensuring compliance and quality from the outset.

• Transformation roadmap is structured in three concurrent phases, with execution already ahead of schedule and the long-range plan (LRP) now set for February 2025.

• Emphasis on attractive end markets and a W-2 sales structure to drive sustainable growth and operational leverage.

• Business continuity and early performance post-spin have exceeded expectations, with initial earnings beating and raising guidance.

Financial performance and guidance

• Revenue growth is the primary metric, targeting 4%-6% market growth rates, with additional focus on margin expansion and free cash flow improvement.

• Q2 results exceeded expectations, prompting a guidance raise of $80M-$160M in revenue upside.

• Second half of the year expected to see flattish growth, with Q3 flat to down and Q4 benefiting from easier comps.

• Full-year EBIT margin guidance reiterated at 21%-23%, with operating expenses expected to rise due to public company stand-up costs.

• Headwinds for 2025 include higher product costs from 3M, increased operating expenses, and higher interest and normalized tax rates.

Operational initiatives and portfolio optimization

• SKU rationalization program removed 5% (3,500) of SKUs in wave one with minimal revenue impact; wave two under review for further optimization.

• Timing of SKU rationalization benefits shifted to 2025, with annualization effects into 2026.

• Portfolio optimization and potential divestitures are under active review, with MedSurg identified as a core focus area.

• Capital allocation prioritizes debt paydown over the next 24 months, with $200M already repaid; no current plans for dividends or share repurchases.

• Small, bolt-on acquisitions in high-growth submarkets are planned post-deleveraging to build scale and leverage the W-2 sales model.